Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

H. Wiendl¹, N. De Stefano², F. Barkhof^{3,4}, X. Montalban⁵, A. Achiron⁶, T. Derfuss⁷, A. Chan⁸, S. Hodgkinson⁹, A. Prat¹⁰, L. Leocani¹¹, K. Schmierer^{12,13}, F. Sellebjerg^{14,15}, P. Vermersch¹⁶, H. Jin¹⁷, E. Järvinen¹⁷, A. Chudecka¹⁸, L. Gardner¹⁹

¹Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany; ²Department of Medicine, Surgery and Neuroscience, University of Siena, Italy; ³Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands and ⁴UCL Institute of Neurology, London, UK; ⁵Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; ⁶Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel; ⁷Department of Neurology, University Hospital Basel, Basel, Switzerland; ⁸Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; ⁹Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, NSW; Australia; ¹⁰Department of Neurosciences, Université de Montréal, QC, Canada; ¹¹Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy; ¹²The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK and ¹³Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK; ¹⁴Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark and ¹⁵Department of Clinical Medicine, University of Copenhagen, Denmark; ¹⁶Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France; ¹⁷the healthcare business of Merck KGaA, Darmstadt, Germany; ¹⁸Cytel Inc., Geneva, Switzerland; ¹⁹EMD Serono, Billerica, MA, USA

Disclosures and Acknowledgements

Medical writing assistance was provided by Ruth Butler-Ryan and Joseph Ward of inScience Communications, Springer Healthcare Ltd., UK. The study was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)

Disclosures: HW is member of scientific advisory boards/steering committees for Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva. He received speaker honoraria and travel support from Bayer, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, the healthcare business of Merck KGaA, Darmstadt, Germany, Omniamed, Novartis, Sanofi, and Teva. He received compensation as a consultant from Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Omniamed, Roche, and Sanofi. He has received research support from Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Sanofi, and Teva, as well as German Ministry for Education and Research (BMBF), German Research Foundation (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Münster, and RE Children's Foundation. NDS is a consultant for Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva; has grants or grants pending from FISM and Novartis, is on the speakers' bureaus of Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva; and has received travel funds from the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva. **FB** is supported by the NIHR Biomedical Research Centre at UCLH and is a consultant to Biogen, Combinostics, IXICO, the healthcare business of Merck KGaA, Darmstadt, Germany, and Roche. **XM** has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with AbbVie, Actelion (Janssen/J&J), Alexion, Biogen, Celgene (BMS), EMD Serono, Immunic, Janssen, MedDay, the healthcare business of Merck KGaA, Darmstadt, Germany, Mylan, Nervgen, Novartis, Roche, Sandoz, Sanofi, Teva, TG Therapeutics, Excemed, MSIF, and NMSS. AA has received honoraria or consulting fees from Bayer, Biogen, Celgene (BMS), the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, and Sanofi; and research support from Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Roche, and Sanofi. TD serves on scientific advisory boards for Bayer, Actelion (Janssen/J&J), Biogen, Celgene (BMS), GeNeuro, MedDay, the healthcare business of Merck KGaA, Darmstadt, Germany, Mitsubishi Pharma, Novartis, Roche, and Sanofi; has received funding for travel and/or speaker honoraria from Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, and Sanofi; and receives research support from Biogen, the European Union, Novartis, Roche, the Swiss MS Society, and the Swiss National Foundation. AC has received speakers / board honoraria from Actelion (Janssen/J&J), Almirall, Bayer, Biogen, Celgene (BMS), the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva, all for hospital research support from Biogen, Sanofi, and UCB, the European Union, and the Swiss National Foundation. He serves as associate editor of the European Journal of Neurology, on the editorial board for Clinical and Translational Neuroscience, and as topic editor for the Journal of International Medical Research. SH serves on advisory boards for Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, and Sanofi. She has received money for travel and speaker honoraria from Bayer, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, and Sanofi. AP has received honoraria and operating grants from pharmaceutical companies. **LL** has received honoraria for consulting services or speaking activities from Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, and Roche; and research support from Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, and Novartis; speaking honoraria from, and/or served in an advisory role for, Amgen-Gensenta, Biogen, EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva; and remuneration for teaching activities from AcadeMe, Medscape, and the Neurology Academy. FS has served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, Celgene (BMS), EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva. PV has received honoraria or consulting fees from AB Science, Biogen, Celgene (BMS), Imcyse, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi, and Teva; and research support from Novartis, Roche, and Sanofi. HJ and EJ are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. ACHu is an employee of Cytel Inc., Geneva Branch, Switzerland, funded by the healthcare business of Merck KGaA, Darmstadt, Germany to perform statistical analyses for this study. LG is an employee of EMD Serono, Billerica, MA, USA.

Previously presented at ACTRIMS 2023 Forum (February 24–26, 2023)





- The MAGNIFY-MS (NCT03364036) BB analysis aimed to characterize the effect of cladribine tablets (3.5 mg/kg cumulative dose over 2 years) on BBs in patients with highly active RMS^{*}.
- Previously published data highlighted immunophenotyping of small subset of patients (n=57)after the first course of treatment.^[1]
- This presentation includes M24 data for all patients who received the full treatment course (N=270).



• To describe BB dynamics over 2 years of treatment with cladribine tablets 3.5 mg/kg, including immune cell subsets, serum proteins, and intracellular cytokines.

*Highly active RMS was defined as one relapse in the previous year and at least one T1 Gd+ lesion, or 9 or more T2 lesions while on therapy with other DMTs; or 2 or more relapses in the previous year whether on DMT or not. **BB**, blood biomarker; **DMT**, disease-modifying therapy; **Gd+**, gadolinium enhancing; **M**, month; **RMS**, relapsing multiple sclerosis

Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are indicated for the treatment of patients with MS in the United States (relapsing forms of MS, including relapsing-remitting disease and active secondary progressive disease, in adults).


REFERENCES 1. Wiendl H, et al. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200048





MAGNIFY-MS Study Assessments

• MAGNIFY-MS was a 2-year, phase IV, open-label, single-arm study in which eligible patients with highly active RMS received cladribine tablets 3.5 mg/kg.








B-Cell and T-Cell Panel (FAS)

Median B-Lymphocyte Count (10⁶/L)



 There was continuous suppression of median
B memory cells, while median regulatory, transitional, and naïve B cells repopulated to above BL levels.

BL, baseline; CD, cluster of differentiation; CM, central memory; EM, effector memory; FAS, full analysis set; M, month; Q1:Q3, quartile range; reg, regulatory; Th, T helper

Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are indicated for the treatment of patients with MS in the United States (relapsing forms of MS, including relapsing-remitting disease and active secondary progressive disease, in adults).



Median T-Lymphocyte Count (10⁶/L)


B cell subset	Median percentage change from BL			
	M12	M24		
Memory	-86.90	-89.29		
Regulatory	+30.64	+1.62		
Transitional	+11.92	+6.30		
Naïve	+1.63	+10.85		

seen from the first visit (M3) onwards; **no repopulation to BL levels** was observed.



NK-Cell Panel (FAS)

Median NK-cell Count (10⁶/L)



Increased median levels above BL from M12 onwards were detected for CD16^{low}CD56^{bright} cells (M24, +17.21%) • and **NKp46 cells** (M24, +77.70%).

BL, baseline; CD, cluster of differentiation; CM, central memory; EM, effector memory; FAS, full analysis set; M, month; Q1:Q3, quartile range; reg, regulatory; Th, T helper

Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are indicated for the treatment of patients with MS in the United States (relapsing forms of MS, including relapsing-remitting disease and active secondary progressive disease, in adults).




Median Percentage Change From Baseline

	Time point (months)					
)e	М3	M6	M12	M15	M18	M24
^{ght} CD56 ^{dim}	-36.13	-25.61	-11.05	-35.05	-24.99	-12.94
CD56 ^{bright}	-8.94	3.72	2.56	4.77	30.13	17.21
	-20.85	-22.38	29.49	28.42	71.73	77.70
	-32.50	-21.78	-8.10	-28.56	-21.47	-13.76
S	-31.15	-22.18	-7.10	-27.70	-18.38	-13.05



Serum Proteins (FAS)

Serum Immunoglobulins Percentage Change From Baseline



Time point (months) Median values МЗ BL M6 M12 M15 M18 M24 IgM absolute value, g/L 1.141.11.01 0.95 0.79 0.8 0.77 IgM percentage change -13.38 -19.61 -27.33 -30.65 -31.49 -6.98 from BL IgG absolute value, g/L 10.6 10.3 10.6 10.4 10.35 10.7 10.6 IgG percentage change 5.00 3.71 1.05 4.90 2.40 2.99 from **BL**


Normal reference range IgG: 5.65–17.65 g/L; IgM: 0.40–2.30 g/L

IgM and IgG levels remained within reference ranges for most patients, and sNfL levels were reduced at months 12 and 24 compared with BL.

BL, baseline; FAS, full analysis set; Ig, immunoglobulin; M, month; Q1:Q3, quartile range; sNfL, serum neurofilament; WSR, Wilcoxon signed rank test


Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are indicated for the treatment of patients with MS in the United States (relapsing forms of MS, including relapsing-remitting disease and active secondary progressive disease, in adults).





Wilcoxon signed rank test comparing data at the respective Visit versus data at BL.





•

Q1:Q3, quartile range; TNFa, tumor necrosis factor alpha





- Previously published data characterized the specific patterns of immune cell dynamics over 12 months. In this 2-year analysis, multifaceted changes consistent with immune reconstitution effect were detected following cladribine tablets treatment, including novel observations regarding increase in specific NK cell subsets and dynamics of intracellular cytokine producing T and B cells.
- Median immune cell changes include: •
 - Continuous suppression of memory B cells, and repopulation of regulatory, transitional, and naïve B cells at M24 to above BL levels.
 - No repopulation of T cells to BL levels.
 - Increase in CD16^{low}CD56^{bright} and NKp46 cells after full treatment course.
- Serum proteins (for most patients):
 - No decrease was observed in median serum IgG levels. Reduction in median IgM levels was observed, however, IgG and IgM levels remained within the normal ranges.
 - Reduced median serum NfL levels at M12 and M24 indicate that treatment with cladribine tablets reduced neuroaxonal damage.
- Intracellular cytokines: •
 - Reduction in median pro-inflammatory cytokine-producing B cells (IL-6⁺) and T cells (GMCSF⁺, TNFa⁺, IFN γ^+), and an increase in median anti-inflammatory cytokine-producing T cells (IL-4+) above Baseline level, suggest a positive treatment response.

BL, baseline; CD, cluster of differentiation; GMCSF, granulocyte-macrophage colony-stimulating factor; Ig, immunoglobulin; IFNy, interferon gamma; IL, interleukin; Nfl, neurofilament; NK, natural killer; TNFa, tumor necrosis factor alpha



Appendix





- Blood samples from patients in MAGNIFY-MS were collected at baseline and M3, 6, 12, 15, 18, and 24 after treatment initiation for immune cell characterization, measurement of immunoglobulins IgG and IgM, and sNfL analysis.
- Immune cell subtypes were analyzed by flow cytometry and were detected using surface cell markers. sNfL was analyzed with Quanterix Simoa immunoassay.
- Intracellular cytokine analyses were performed for a subset of patients in the BB sub-study and required blood collection at additional time points (M1, 2, and 14).
- All analyses were performed without adjustment for multiplicity.

BB, blood biomarker; Ig, immunoglobulins; M, month; MRI, magnetic resonance imaging; sNFL, serum neurofilament






Patient characteristics

- A total of **270 patients** enrolled in the main study were analyzed (**BB sub-study, n=57**). There were **180 female patients** (66.7%), and **118** (43.7%) were **aged between >40 – <65 years**.
- The patient characteristics in the sub-study corresponds to the overall patient population participating in the core • MAGNIFY-MS study.

Female, n (%)
Age >40 - <65 years, n (%)
Time since onset of MS in months, mean ± SD
Time since diagnosis in months, mean ± SD
Time since first relapse in months, mean ± SD
Number of relapses within 12 months prior to Baseline, n (%)
0
1
2
>2
EDSS score ≤3 at Baseline, n (%)
Median EDSS score at Baseline (range)
Number of previous DMTs, n (%)
0
1
2
>2
BB , blood biomarker; DMT , disease-modifying therapy; EDSS , Expanded Disability Status Scale; MS , multiple sclerosis; SD , st



Main study population (N=270)	BB sub-study population (n=57)
180 (66.7)	35 (61.4)
118 (43.7)	22 (38.6)
84.90 ± 85.472	84.94 ± 93.385
60.87 ± 74.489	52.54 ± 67.413
54.44 ± 72.583	52.63 ± 80.704
3 (1.1)	2 (3.5)
102 (37.8)	15 (26.3)
133 (49.3)	29 (50.9)
32 (11.9)	11 (19.3)
204 (75.6)	42 (73.7)
2.0 (0.0-5.0)	2.5 (0.0-5.0)
117 (43.3)	30 (52.6)
88 (32.6)	13 (22.8)
50 (18.5)	10 (17.5)
15 (5.6)	4 (7.0)
andard deviation	



Median (Q1:Q3)

- The reductions for IL-6⁺ MFI B cell cytokines and IL-6⁺ MFI Memory B cell cytokines were pronounced in the first year of treatment with cladribine tablets, with highest decrease at Month 12 (median change from baseline: -655.83 and -541.25, respectively).
- The IL-10⁺ MFI B cell cytokines showed some reduction after Month 12, with highest at Month 15 (median change • from baseline: -334.60). The IL-10⁺ MFI Memory B cell cytokines were not affected.


CD, cluster of differentiation; IL, interleukin; MFI, mean fluorescence intensity; Q1:Q3, quartile range

Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are indicated for the treatment of patients with MS in the United States (relapsing forms of MS, including relapsing-remitting disease and active secondary progressive disease, in adults).

----- IL10 MFI B Cells; ----- IL10 MFI Memory B Cells ----- IL6 MFI B Cells ----- IL6 MFI Memory B Cells




Change from Baseline





CD4⁺ T cell cytokines




- The decrease in IFN_Y⁺ MFI CD4⁺ T cell cytokines and GMCSF⁺ MFI CD4⁺ T cell cytokines was observed from • Month 3 (median change from baseline: -1045.25 and -408.50) and continued until Month 15.
- On the contrary, the IL4⁺ MFI CD4⁺ T cell cytokines increased in response to treatment first at Month 3 • (median change from baseline: +460.50), and then also at Month 15.

CD, cluster of differentiation; GMCSF, granulocyte-macrophage colony-stimulating factor; IFNy, interferon gamma; IL, interleukin; MFI, mean fluorescence intensity; Q1:Q3, guartile range TNFa, tumor necrosis factor alpha





CD8⁺ T cell cytokines



- The decrease in IFN_Y⁺ MFI CD8⁺ T cell cytokines and GMCSF⁺ MFI CD8⁺ T cell cytokines was observed since • Month 3 (median change from baseline: -975.00 and -347.00) and continued until Month 15.
- On the contrary, the IL4⁺ MFI CD8⁺ T cell cytokine levels increased at Month 3 (median change from baseline: • +347.75), and then also at Month 15 but were less pronounced than CD4⁺ T cell cytokines.

CD, cluster of differentiation; GMCSF, granulocyte-macrophage colony-stimulating factor; IFNy, interferon gamma; IL, interleukin; MFI, mean fluorescence intensity; Q1:Q3, guartile range TNFa, tumor necrosis factor alpha

